Cargando…
Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences
The global pandemic of COVID-19 has attracted extensive drug searching interets for the new coronavirus SARS-CoV-2. Although currently several of clinically used “old” drugs have been repurposed to this new disease for the urgent clinical investigation, there is still great demand for more effective...
Autores principales: | Wang, Aoli, Sun, Yong, Liu, Qingwang, Wu, Hong, Liu, Juan, He, Jun, Yu, Junling, Chen, Qing Qing, Ge, Yinglu, Zhang, Zhuhui, Hu, Chen, Chen, Cheng, Qi, Ziping, Zou, Fengming, Liu, Feiyang, Hu, Jie, Zhao, Ming, Huang, Tao, Wang, Beilei, Wang, Li, Wang, Wei, Wang, Wenchao, Ren, Tao, Liu, Jing, Sun, Yehuan, Fan, Song, Wu, Qibing, Liang, Chaozhao, Sun, Liangdan, Su, Bin, Wei, Wei, Liu, Qingsong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7700809/ https://www.ncbi.nlm.nih.gov/pubmed/34765997 http://dx.doi.org/10.1186/s43556-020-00018-9 |
Ejemplares similares
-
Clinical efficacy of low-dose emetine for patients with COVID-19: a real-world study
por: Fan, Song, et al.
Publicado: (2021) -
Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus
por: Wang, Junjie, et al.
Publicado: (2023) -
Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
por: Jiang, Zongru, et al.
Publicado: (2020) -
Discovery of a highly potent and selective Bruton’s tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma
por: Liu, Juan, et al.
Publicado: (2020) -
Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)